Editas Medicine shares are trading higher after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.
Portfolio Pulse from Benzinga Newsdesk
Raymond James upgraded Editas Medicine (EDIT) from Market Perform to Outperform and set a $17 price target, causing the stock to trade higher.
June 13, 2023 | 4:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Editas Medicine's stock is trading higher after Raymond James upgraded it to Outperform and set a $17 price target.
The upgrade from Raymond James is a positive signal for Editas Medicine, as it indicates increased confidence in the company's performance. The new price target of $17 suggests potential upside for the stock, which is likely to attract more investors and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100